Danimer Scientific, Inc. Logo

Danimer Scientific, Inc.

DNMR

(0.8)
Stock Price

8,64 USD

-21.95% ROA

-48.31% ROE

-0.39x PER

Market Cap.

52.813.596,00 USD

169.9% DER

0% Yield

-325.87% NPM

Danimer Scientific, Inc. Stock Analysis

Danimer Scientific, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Danimer Scientific, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.44x), the stock offers substantial upside potential at a bargain price.

2 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

3 ROE

Negative ROE (-54.65%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (-29.9%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 DER

The stock is burdened with a heavy load of debt (122%), making it financially unstable and potentially risky for investors.

6 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (-1), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Danimer Scientific, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Danimer Scientific, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Buy

Danimer Scientific, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Danimer Scientific, Inc. Revenue
Year Revenue Growth
2018 30.454.000
2019 32.344.000 5.84%
2020 47.333.000 31.67%
2021 58.749.000 19.43%
2022 53.218.000 -10.39%
2023 43.792.000 -21.52%
2023 46.684.000 6.19%
2024 30.512.000 -53%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Danimer Scientific, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2018 5.136.000
2019 5.482.000 6.31%
2020 7.851.000 30.17%
2021 20.270.000 61.27%
2022 31.939.000 36.54%
2023 27.532.000 -16.01%
2023 21.440.000 -28.41%
2024 12.544.000 -70.92%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Danimer Scientific, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2018 7.258.000
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Danimer Scientific, Inc. EBITDA
Year EBITDA Growth
2018 2.346.000
2019 -4.164.000 156.34%
2020 -10.298.000 59.56%
2021 -88.800.000 88.4%
2022 -48.230.000 -84.12%
2023 -124.956.000 61.4%
2023 -96.127.000 -29.99%
2024 -45.304.000 -112.18%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Danimer Scientific, Inc. Gross Profit
Year Gross Profit Growth
2018 11.245.000
2019 11.107.000 -1.24%
2020 11.457.000 3.05%
2021 884.000 -1196.04%
2022 -10.414.000 108.49%
2023 -30.948.000 66.35%
2023 -35.952.000 13.92%
2024 -36.944.000 2.69%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Danimer Scientific, Inc. Net Profit
Year Net Profit Growth
2018 208.000
2019 -19.514.000 101.07%
2020 -14.969.000 -30.36%
2021 -60.107.000 75.1%
2022 -179.758.000 66.56%
2023 -160.636.000 -11.9%
2023 -155.473.000 -3.32%
2024 -90.644.000 -71.52%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Danimer Scientific, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2018 0
2019 -1 0%
2020 0 0%
2021 -1 0%
2022 -2 100%
2023 -2 0%
2023 -2 0%
2024 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Danimer Scientific, Inc. Free Cashflow
Year Free Cashflow Growth
2018 -5.287.000
2019 -38.233.000 86.17%
2020 -52.065.000 26.57%
2021 -248.374.000 79.04%
2022 -226.323.000 -9.74%
2023 -12.861.000 -1659.76%
2023 -74.949.000 82.84%
2024 -20.770.000 -260.85%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Danimer Scientific, Inc. Operating Cashflow
Year Operating Cashflow Growth
2018 323.000
2019 -1.673.000 119.31%
2020 -13.797.000 87.87%
2021 -62.963.000 78.09%
2022 -61.837.000 -1.82%
2023 -10.180.000 -507.44%
2023 -47.264.000 78.46%
2024 -18.970.000 -149.15%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Danimer Scientific, Inc. Capital Expenditure
Year Capital Expenditure Growth
2018 5.610.000
2019 36.560.000 84.66%
2020 38.268.000 4.46%
2021 185.411.000 79.36%
2022 164.486.000 -12.72%
2023 2.681.000 -6035.25%
2023 27.685.000 90.32%
2024 1.800.000 -1438.06%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Danimer Scientific, Inc. Equity
Year Equity Growth
2018 27.188.000
2019 16.576.000 -64.02%
2020 438.904.000 96.22%
2021 500.265.000 12.27%
2022 377.612.000 -32.48%
2023 278.020.000 -35.82%
2023 304.281.000 8.63%
2024 234.028.000 -30.02%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Danimer Scientific, Inc. Assets
Year Assets Growth
2018 114.250.000
2019 144.573.000 20.97%
2020 546.201.000 73.53%
2021 838.597.000 34.87%
2022 712.270.000 -17.74%
2023 730.285.000 2.47%
2023 720.966.000 -1.29%
2024 666.540.000 -8.17%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Danimer Scientific, Inc. Liabilities
Year Liabilities Growth
2018 87.062.000
2019 127.997.000 31.98%
2020 107.297.000 -19.29%
2021 338.332.000 68.29%
2022 334.658.000 -1.1%
2023 452.265.000 26%
2023 416.685.000 -8.54%
2024 432.512.000 3.66%

Danimer Scientific, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.34
Net Income per Share
-1.11
Price to Earning Ratio
-0.39x
Price To Sales Ratio
1.33x
POCF Ratio
-2.06
PFCF Ratio
-1.59
Price to Book Ratio
0.22
EV to Sales
10.86
EV Over EBITDA
-5.6
EV to Operating CashFlow
-17.42
EV to FreeCashFlow
-13
Earnings Yield
-2.54
FreeCashFlow Yield
-0.63
Market Cap
0,05 Bil.
Enterprise Value
0,43 Bil.
Graham Number
7.09
Graham NetNet
-3.16

Income Statement Metrics

Net Income per Share
-1.11
Income Quality
0.19
ROE
-0.48
Return On Assets
-0.19
Return On Capital Employed
-0.15
Net Income per EBT
1
EBT Per Ebit
1.3
Ebit per Revenue
-2.5
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.48
Stock Based Compensation to Revenue
0.74
Gross Profit Margin
-0.86
Operating Profit Margin
-2.5
Pretax Profit Margin
-3.25
Net Profit Margin
-3.26

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.21
Free CashFlow per Share
-0.28
Capex to Operating CashFlow
-0.34
Capex to Revenue
0.21
Capex to Depreciation
0.28
Return on Invested Capital
-0.16
Return on Tangible Assets
-0.22
Days Sales Outstanding
132.57
Days Payables Outstanding
14.2
Days of Inventory on Hand
129.6
Receivables Turnover
2.75
Payables Turnover
25.7
Inventory Turnover
2.82
Capex per Share
0.07

Balance Sheet

Cash per Share
0,35
Book Value per Share
2,01
Tangible Book Value per Share
1.35
Shareholders Equity per Share
2.01
Interest Debt per Share
3.37
Debt to Equity
1.7
Debt to Assets
0.6
Net Debt to EBITDA
-4.92
Current Ratio
4.52
Tangible Asset Value
0,16 Bil.
Net Current Asset Value
-0,35 Bil.
Invested Capital
597499000
Working Capital
0,07 Bil.
Intangibles to Total Assets
0.11
Average Receivables
0,02 Bil.
Average Payables
0,00 Bil.
Average Inventory
26133000
Debt to Market Cap
7.53

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Danimer Scientific, Inc. Dividends
Year Dividends Growth

Danimer Scientific, Inc. Profile

About Danimer Scientific, Inc.

Danimer Scientific, Inc., a performance polymer company, develops, produces, and provides bioplastic replacements for traditional petroleum-based plastics. It produces polyhydroxyalkanoate, a biodegradable plastic feedstock alternative used in a range of plastic applications, including films, straws, food containers, and other things under the Nodax brand name; polylactic acid-based resins for coating disposable paper cups; and other biopolymers. The company offers its products for biopolymers, including additives, aqueous coatings, fibers, filaments, films, thermoforming, and injection-molded articles. It also markets its products to consumer packaging brand owners, converters, and manufacturers in the plastics industry. Danimer Scientific, Inc. was founded in 2004 and is headquartered in Bainbridge, Georgia.

CEO
Mr. Stephen E. Croskrey
Employee
257
Address
140 Industrial Boulevard
Bainbridge, 39817

Danimer Scientific, Inc. Executives & BODs

Danimer Scientific, Inc. Executives & BODs
# Name Age
1 Mr. Michael A. Hajost
Chief Financial Officer
70
2 Mr. Michael Smith
Chief Operating Officer
70
3 Russ Zukowski
Vice President of Corporate Finance
70
4 Mr. Phillip D. Van Trump
Chief Science & Technology Officer
70
5 Mr. Anthony L. Austin
Chief Human Resource Officer
70
6 Mr. Stephen Albert Martin Esq.
Corporate Secretary & Chief Legal Officer
70
7 Mr. Richard J. Hendrix
Interim Executive Independent Chairman
70
8 Mr. Scott C. Tuten
Chief Marketing & Sustainability Officer
70
9 Mr. Stephen E. Croskrey
Chief Executive Officer & Director
70
10 James Palczynski
Investor Relations Officer
70

Danimer Scientific, Inc. Competitors